JACOBS LEVY EQUITY MANAGEMENT, INC

Position in DSGN — Design Therapeutics, Inc.

CIK 884414 FLORHAM PARK, NJ

Position in DSGN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$8,184,188

+$5,105,132 QoQ

Shares Held

565,597

+95.4% QoQ

Ownership

0.904%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

#21

of 136 holders

Holding Since

Jun 2023

11 quarters on record

Voting authority Sole 91% Shared 0% None 9%

Healthcare · as of Jun 30, 2026

JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. DSGN ranks #19 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	256,503	$159,939,880
2	RARE	Ultragenyx Pharmaceutical Inc.	2,939,719	$98,157,217
3	INCY	Incyte Corp	731,774	$82,953,900
4	CORT	Corcept Therapeutics Inc	695,532	$60,476,507
5	HALO	Halozyme Therapeutics, Inc.	322,377	$25,232,447
6	EXEL	Exelixis, Inc.	415,650	$22,615,516
7	AUPH	Aurinia Pharmaceuticals Inc.	1,231,516	$20,898,826
8	ALNY	Alnylam Pharmaceuticals, Inc.	60,986	$18,358,615

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$8,184,188	565,597	+95.4%	Shares	Sole	2026-08-14
2026-03-31	$3,079,056	289,385	+48.7%	Shares	Sole	2026-05-15
2025-12-31	$1,825,451	194,611	+1341.5%	Shares	Sole	2026-02-13
2025-06-30	$45,498	13,501	-22.8%	Shares	Sole	2025-08-14
2025-03-31	$67,480	17,482	-4.3%	Shares	Sole	2025-05-15
2024-12-31	$112,670	18,261	-93.5%	Shares	Sole	2025-02-14
2024-09-30	$1,507,857	280,271	-41.2%	Shares	Sole	2024-11-14
2024-06-30	$1,595,464	476,258	-5.1%	Shares	Sole	2024-08-14
2024-03-31	$2,023,140	502,020	-8.6%	Shares	Sole	2024-05-15
2023-12-31	$1,455,162	549,118	+3310.7%	Shares	Sole	2024-02-14
2023-06-30	$101,430	16,100	—	Shares	Sole	2023-08-14
No filing history on record for this holder in this stock.